VNDA
Vanda Pharmaceuticals Inc. Healthcare - Biotechnology Investor Relations →
Vanda Pharmaceuticals Inc. (VNDA) closed at $5.80 as of 2026-06-19, trading 0.1% below its 200-week moving average of $5.80. This places VNDA in the below line zone. The stock is currently moving closer to the line, down from 0.7% last week. With a 14-week RSI of 16, VNDA is in oversold territory.
Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.69 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.
Over the past 1005 weeks of data, VNDA has crossed below its 200-week moving average 19 times. On average, these episodes lasted 30 weeks. The average one-year return after crossing below was -17.5%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $349 million, VNDA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -60.5%. The stock trades at 1.1x book value.
Share count has increased 4.1% over three years, indicating dilution.
Over the past 19.3 years, a hypothetical investment of $100 in VNDA would have grown to $24, compared to $752 for the S&P 500. VNDA has returned -7.2% annualized vs 11.0% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: VNDA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After VNDA Crosses Below the Line?
Across 18 historical episodes, buying VNDA when it crossed below its 200-week moving average produced an average return of -22.2% after 12 months (median -25.0%), compared to +4.9% for the S&P 500 over the same periods. 18% of those episodes were profitable after one year. After 24 months, the average return was -11.9% vs +19.6% for the index.
Each line shows $100 invested at the moment VNDA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. VNDA currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from VNDA's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
VNDA has crossed below its 200-week MA 19 times with an average 1-year return of +-17.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2007 | Oct 2007 | 10 | 15.9% | -93.9% | -64.4% |
| Oct 2007 | May 2009 | 81 | 95.2% | -94.7% | -63.1% |
| Oct 2009 | Nov 2009 | 1 | 0.1% | -28.3% | -43.1% |
| Jan 2010 | Feb 2010 | 1 | 2.3% | -20.0% | -42.1% |
| Apr 2010 | Dec 2010 | 34 | 38.0% | -4.2% | -31.0% |
| Jan 2011 | Apr 2011 | 13 | 11.7% | -36.0% | -28.0% |
| May 2011 | Jun 2011 | 7 | 5.1% | -41.0% | -20.7% |
| Aug 2011 | May 2013 | 94 | 56.5% | -40.7% | -14.1% |
| Nov 2013 | Nov 2013 | 1 | 6.0% | +88.9% | -7.1% |
| Nov 2015 | Dec 2015 | 2 | 6.4% | +74.1% | -35.3% |
| Jan 2016 | May 2016 | 20 | 19.2% | +87.0% | -29.4% |
| May 2019 | Nov 2019 | 27 | 20.0% | -25.0% | -62.1% |
| Dec 2019 | Feb 2021 | 58 | 48.7% | -18.2% | -63.9% |
| Mar 2021 | Apr 2021 | 2 | 3.0% | -25.9% | -62.5% |
| Aug 2021 | Aug 2021 | 3 | 2.0% | -34.1% | -63.7% |
| Nov 2021 | Dec 2021 | 2 | 3.2% | -32.7% | -64.2% |
| Dec 2021 | Dec 2025 | 207 | 70.6% | -52.9% | -63.0% |
| Feb 2026 | Feb 2026 | 2 | 5.6% | N/A | -4.8% |
| Jun 2026 | Ongoing | 1+ | 0.1% | Ongoing | N/A |
| Average | 30 | — | +-17.5% | — |
Frequently Asked Questions
Is VNDA below its 200-week moving average?
Yes. As of 2026-06-19, Vanda Pharmaceuticals Inc. (VNDA) is trading 0.1% below its 200-week moving average of $5.80. The current price is $5.80.
What is VNDA's 200-week moving average price?
Vanda Pharmaceuticals Inc.'s 200-week moving average is $5.80 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when VNDA drops below its 200-week moving average?
VNDA has crossed below its 200-week moving average 19 times in our data. The average one-year return after these crossings was -17.5%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 30 weeks on average.
Is VNDA a good value right now?
Here's what our data says about VNDA as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 16 (oversold). Free cash flow is currently negative. Return on equity is -60.5%. Price-to-book is 1.1x. This is not a buy or sell recommendation — always do your own research.
How does VNDA compare to the S&P 500?
Over the past 19.3 years, $100 invested in VNDA would have grown to $24, compared to $752 for the S&P 500. That's -7.2% annualized vs 11.0% for the index. VNDA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19